首页 正文

Review Biochemical Society transactions. 2007 Aug;35(Pt 4):802-6. doi: 10.1042/BST0350802 Q24.32025

Targeting aggressive B-cell lymphomas with cell-penetrating peptides

靶向作用于B细胞淋巴瘤的穿膜肽 翻译改进

A Melnick  1

作者单位 +展开

作者单位

  • 1 Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA. amelnick@aecom.yu.edu
  • DOI: 10.1042/BST0350802 PMID: 17635152

    摘要 Ai翻译

    DLBCL (diffuse large B-cell lymphoma) is the most common subtype of non-Hodgkin's lymphoma. Current therapy for patients includes chemotherapy and monoclonal antibodies. Although oncogene-targeted therapy is dramatically successful for patients with certain kinds of leukaemias, there are no such agents yet for DLBCL. One reason for this is that several key oncogenes involved in DLBCL pathogenesis are transcription factors, which are difficult to therapeuti... ...点击完成人机验证后继续浏览
    Copyright © Biochemical Society transactions. 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:Biochemical society transactions

    缩写:BIOCHEM SOC T

    ISSN:0300-5127

    e-ISSN:1470-8752

    IF/分区:4.3/Q2

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Targeting aggressive B-cell lymphomas with cell-penetrating peptides